Isentress Related Clinical Trials
Raltegravir Switch for Toxicity or Adverse Events [Recruiting]
Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1 [Recruiting]
The Effect of Rifapentine on Raltegravir [Recruiting]
Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients [Recruiting]
Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men [Recruiting]
Management of HIV-1 Patients Treated With Antiretroviral Combination Therapy Including Raltegravir (0518-138)(MK0518-138) [Recruiting]
A Study to Assess the Efficacy of Raltegravir, Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) [Not yet recruiting]
Raltegravir Therapy for Women With HIV and Fat Accumulation [Recruiting]
A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With HIV-1 [Recruiting]
Safety and Effectiveness of Raltegravir (MK-0518) in Treatment-Experienced, HIV-Infected Children and Adolescents [Recruiting]
Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir [Recruiting]
Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis [Not yet recruiting]
A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects [Not yet recruiting]
Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women [Not yet recruiting]
Effect of Antacids on the Pharmacokinetics of Raltegravir [Recruiting]
BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated. [Recruiting]
Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin. [Not yet recruiting]
Atripla to Raltegravir Switch Study [Recruiting]
Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects [Recruiting]
A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV [Not yet recruiting]
Raltegravir in the Swiss HIV Cohort Study [Recruiting]
Study of Raltegravir Versus Nucleotide Reverse Transcriptase Inhibitors (NRTIs) as a Backbone in HIV-Infected Subjects Switched From a Stable Boosted Protease Inhibitor (PI) Regimen [Recruiting]
Levels of Raltegravir in the Female Genital Tissue [Recruiting]
Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis [Recruiting]
Effects of Raltegravir (Isentress®) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers [Recruiting]
Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART. [Recruiting]
Renal Transplantation and Raltegravir in HIV-Infected Patients [Recruiting]
Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study [Recruiting]
Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients [Recruiting]
Patient Preference, Sleep Quality, and Anxiety/Depression: A Comparison of Raltegravir and Efavirenz [Recruiting]
Simplification From Protease Inhibitors to Raltegravir [Recruiting]
Addition of Raltegravir to Established Antiretroviral Suppressive Therapy [Not yet recruiting]
Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP) [Recruiting]
Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients [Not yet recruiting]
The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA) [Recruiting]
Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression [Recruiting]
Buprenorphine/Raltegravir Pharmacokinetic Interaction Study [Recruiting]
Efficacy of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load [Recruiting]
Raltegravir and Atazanavir Dosing Strategy Study [Recruiting]
A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir [Recruiting]
A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Women [Recruiting]
Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects [Recruiting]
Raltegravir Substitution for Enfuvirtide in Patients Suffering From Injection Site Reactions (ISRs): The Raleve Pilot Study [Recruiting]
A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients [Recruiting]
Raltegravir as Early Therapy in African-Americans Living With HIV Study [Recruiting]
Kaletra-isentress Treatment Evaluation [Recruiting]
Pilot Study of the Impact of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Undetectable Plasma Virus [Recruiting]
Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment [Recruiting]
Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-Infected Patients [Recruiting]
BRAVO: Background Regimen of Raltegravir on Virologic Outcome [Recruiting]
A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen [Not yet recruiting]
Pharmacokinetic Study on Raltegravir and Lamotrigine [Recruiting]
Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy [Recruiting]
Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid [Recruiting]
Antiretroviral Therapy Intensification With Raltegravir and/or Hyper-Immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response: The CORAL Study [Not yet recruiting]
Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients [Recruiting]
HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy [Recruiting]
Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women. [Recruiting]
Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen [Recruiting]
Abacavir Pharmacokinetic Study [Recruiting]
Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) [Recruiting]
Raltegravir Added to Stable Highly Active Antiretroviral Therapy (HAART) in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery [Recruiting]
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) [Recruiting]
CCRC: A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Raltegravir Therapy [Recruiting]
Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals [Recruiting]
Comparing Raltegravir Genital Tract Distribution in HIV-Infected Men and Women [Recruiting]
Raltegravir Therapy for Women With HIV and Fat Accumulation [Not yet recruiting]
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) [Recruiting]
HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain [Recruiting]
Pharmacokinetics of Raltegravir During Third Trimester Pregnancy and Post-Partum [Recruiting]
Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients [Recruiting]
Raltegravir vs. Atazanavir in Combination With Truvada� for the Treatment of Antiretroviral na�ve HIV Infected Patients [Recruiting]
Raltegravir Intensification in HIV-Infected Patients [Recruiting]
Integrase Inhibitor (MK-0518) Viral Decay [Not yet recruiting]
HIV Non Occupational Post-Exposure Prophylaxis (PEP) [Recruiting]
Switching From PI to RALtegravir in HIV Stable Patients [Recruiting]
Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection [Recruiting]
Pilot Opened Trial in HIV-Infected Patients Including an Investigational Marketed Product [Recruiting]
Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients [Recruiting]
Phase IIB Pilot of Atazanavir + Raltegravir [Recruiting]
Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF) [Not yet recruiting]
Depletion of Latent HIV in CD4 Cells [Not yet recruiting]
The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection [Not yet recruiting]
Standard Antiretroviral v. Multi-Class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01) [Recruiting]
Sex, Aging and Antiretroviral Pharmacokinetics [Recruiting]
Optimizing Treatment for Treatment-Experienced, HIV-infected People [Recruiting]
Clinical Trial of CNS-targeted HAART (CIT2) [Recruiting]
Safety and Effectiveness of Addition of Maraviroc to ART Regimens in HIV-Infected Adults With Suboptimal CD4 T-Cell Count Recovery Despite Sustained Virologic Suppression [Recruiting]
|
